Browsing by Subject "MAO"
Now showing items 1-10 of 30
-
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B
(Elsevier, 2019)The present study investigates the monoamine oxidase (MAO) inhibition properties of a series of ten 5-aryl-1,3,4-oxadiazol-2-ylbenzenesulfonamides. The target compounds were synthesized by dehydration of the corresponding ... -
2-Acetylphenol analogs as potent reversible monoamine oxidase inhibitors
(Dove Press, 2015)Based on a previous report that substituted 2-acetylphenols may be promising leads for the design of novel monoamine oxidase (MAO) inhibitors, a series of C5-substituted 2-acetylphenol analogs (15) and related compounds ... -
2-Benzylidene-1-indanone derivatives as inhibitors of monoamine oxidase
(Elsevier, 2016)In the present study, a series of twenty-two 2-benzylidene-1-indanone derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The 2-benzylidene-1-indanone derivatives ... -
2-Heteroarylidene-1-indanone derivatives as inhibitors of monoamine oxidase
(Elsevier, 2016)In the present study a series of fifteen 2-heteroarylidene-1-indanone derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. These compounds are structurally related ... -
3-Coumaranone derivatives as inhibitors of monoamine oxidase
(Dove Press, 2015)The present study examines the monoamine oxidase (MAO) inhibitory properties of a series of 20 3-coumaranone [benzofuran-3(2H)-one] derivatives. The 3-coumaranone derivatives are structurally related to series of α-tetralone ... -
C6- and C7-substituted 3,4-dihydro-2(1H)-quinolinones as inhibitors of monoamine oxidase
(Thieme, 2017)Purpose Monoamine oxidase (MAO) inhibitors are considered to be useful therapeutic agents and isoform specific inhibitors are employed for the treatment of depression and Parkinson’s disease. MAO inhibitors are also under ... -
The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson’s disease
(MDPI, 2017)l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and ... -
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase
(Elsevier, 2017)The monoamine oxidase (MAO) enzymes are of considerable pharmacological interest and inhibitors are used in the clinic for the treatment of major depressive disorder and Parkinson's disease. A limited number of studies ... -
Evaluation of nitrocatechol bearing cyclic chalcones and related analogues as dual monoamine oxidase and catechol-O-methyltransferase inhibitors
(North-West University (South-Africa), 2020)Parkinson’s disease (PD) is one of the leading causes of disability in the world. A better understanding of the aetiology of this disorder will lead to better medications, and would improve the quality of life for millions ... -
An evaluation of synthetic indole derivatives as inhibitors of monoamine oxidase
(Elsevier, 2016)In a recent study we have shown that several indole-5,6-dicarbonitrile derivatives are potent inhibitors of human monoamine oxidase (MAO) A and B. To expand on these results and to further determine structure–activity ...
